Yunlang She
Overview
Explore the profile of Yunlang She including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen T, Wen J, Shen X, Shen J, Deng J, Zhao M, et al.
NPJ Digit Med
. 2025 Jan;
8(1):69.
PMID: 39875799
Existing prognostic models are useful for estimating the prognosis of lung adenocarcinoma patients, but there remains room for improvement. In the current study, we developed a deep learning model based...
2.
Dong Y, Xu L, Wen J, Si H, Yu J, Chen T, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100763.
PMID: 39758598
Objective: The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the...
3.
Zhao M, Xue G, He B, Deng J, Wang T, Zhong Y, et al.
Nat Commun
. 2025 Jan;
16(1):84.
PMID: 39747216
Diagnosing lung cancer from indeterminate pulmonary nodules (IPLs) remains challenging. In this multi-institutional study involving 2032 participants with IPLs, we integrate the clinical, radiomic with circulating cell-free DNA fragmentomic features...
4.
E H, Zhang L, Yang Z, Xu L, Wang T, Guo J, et al.
J Exp Clin Cancer Res
. 2024 Dec;
43(1):324.
PMID: 39702326
Background: Thymic epithelial tumors (TETs) are infrequent malignancies that arise from the anterior mediastinum. Therapeutic options for TETs, especially thymic carcinoma (TC), remain relatively constrained. This study aims to investigate...
5.
Shen X, Zhao M, Deng J, Chen T, Wen J, Xu L, et al.
Eur J Cardiothorac Surg
. 2024 Sep;
66(3).
PMID: 39298445
Objectives: Despite excellent 5-year survival, there are limited data on the long-term prognostic characteristics of clinical stage IA part-solid lung adenocarcinoma. The objective was to elucidate the dynamics of prognostic...
6.
He Y, Huang L, Deng J, Zhong Y, Chen T, She Y, et al.
Transl Lung Cancer Res
. 2024 Jul;
13(6):1318-1330.
PMID: 38973957
Background: Sleeve lobectomy is a challenging procedure with a high risk of postoperative complications. To facilitate surgical decision-making and optimize perioperative treatment, we developed risk stratification models to quantify the...
7.
Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y, et al.
J Thorac Cardiovasc Surg
. 2024 May;
169(1):242-253.e4.
PMID: 38763304
Objective: Accurately predicting response during neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer remains clinically challenging. In this study, we investigated the effectiveness of blood-based tumor mutational burden (bTMB) and...
8.
Chen T, Wen J, He Y, Zhong Y, Deng J, Chen Q, et al.
Eur J Cardiothorac Surg
. 2024 Mar;
65(4).
PMID: 38539042
Objectives: It has been demonstrated that neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy was safe and feasible referred to neoadjuvant chemotherapy for patients with non-small cell lung cancer undergoing sleeve...
9.
Si H, Xu L, Zhao Y, Su H, Dai C, Xie H, et al.
Ann Thorac Surg
. 2024 Mar;
118(4):825-833.
PMID: 38499219
Background: We aimed to validate the prognostic implication of uncertain resection, R(un), proposed by International Association for the Study of Lung Cancer (IASLC) and evaluate the prognostic value of spread...
10.
Huang S, Zhao M, Li S, Chen T, Zhong Y, Deng J, et al.
Lung Cancer
. 2024 Feb;
189:107472.
PMID: 38320371
Objectives: The Lepidic Component (LP) identifies a subgroup with an excellent prognosis for lung adenocarcinoma (LUAD). Our research aimed to propose an improved pathological T (pT) stage for LUAD based...